Controversies and new approaches to treatment of Langerhans cell histiocytosis (Q41751104)

8 October 2017

1 reference

title

Controversies and new approaches to treatment of Langerhans cell histiocytosis (English)

1 reference

8 October 2017

Arceci RJ

1

1 reference

PubMed ID

9561904

8 October 2017

Brenner MK

series ordinal

2

1 reference

PubMed ID

9561904

8 October 2017

Pritchard J

series ordinal

3

1 reference

8 October 2017

1 April 1998

1 reference

Hematology / Oncology Clinics of North America

8 October 2017

1 reference

8 October 2017

12

1 reference

8 October 2017

339-357

1 reference

8 October 2017

2

1 reference

Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide

8 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Tumor cell survival and resistance to therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Histiocytosis X. Purified (T6+) cells from bone granuloma produce interleukin 1 and prostaglandin E2 in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Cyclosporine therapy for refractory Langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Interferon and disseminated Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

2-Chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Idiopathic central diabetes insipidus followed by progressive spastic cerebral ataxia. Report of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

New perspectives of CD28-B7-mediated T cell costimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

alpha-Interferon treatment for idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Genetic mechanisms of drug resistance. A review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

The use of genetic marking to assess the interaction of sensitive and multidrug-resistant cells in mixed culture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

The contribution of marker gene studies to hemopoietic stem cell therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Genetic marking and manipulation of hematopoietic progenitor cells using retroviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Gene-marking to trace origin of relapse after autologous bone-marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Diabetes insipidus associated with Langerhans cell histiocytosis: is it reversible?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Langerhans' cell histiocytosis and the nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Current role of radiation therapy in the management of histiocytosis-X.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Etoposide in recurrent childhood Langerhans' cell histiocytosis: an Italian cooperative study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Heterogeneity of immunological patterns in Langerhan's histiocytosis and response to crude calf thymic extract in 11 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

The role of cytokines in the pathogenesis of pulmonary Langerhans' cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Allogeneic bone marrow transplantation in a patient with chemotherapy-resistant progressive histiocytosis X

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Combined chemokine and cytokine gene transfer enhances antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelog

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

The Frequency and Natural History of Diabetes Insipidus in Children with Langerhans-Cell Histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Association of Langerhans cell histiocytosis with malignant neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

A monoclonal antibody to cis-urocanic acid prevents the ultraviolet-induced changes in Langerhans cells and delayed hypersensitivity responses in mice, although not preventing dendritic cell accumulation in lymph nodes draining the site of irradiati

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Comparative potency of different UV sources in reducing the density and antigen-presenting capacity of Langerhans cells in C3H mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Histiocytosis X: Does radiotherapy still have a role?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Expression of GM-CSF receptor by Langerhans' cell histiocytosis cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Apoptosis in cancer therapy: crossing the threshold

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Monokine expression in Langerhans' cell histiocytosis and sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Progressive Langerhans cell histiocytosis in an infant with Klinefelter syndrome successfully treated with allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

[Langerhans cell histiocytosis in childhood--results of the DAL-HX 83 study]

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Progressive spinocerebellar degeneration "plus" associated with Langerhans cell histiocytosis: a new paraneoplastic syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Radiation therapy in soft-tissue lesions in histiocytosis X (Langerhans' cell histiocytosis).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Results of treatment of 127 patients with systemic histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Otitis externa in Langerhans' cell histiocytosis--the successful use of topical nitrogen mustard.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Temporal correlation between UV radiation locally-inducible tolerance and the sequential appearance of dermal, then epidermal, class II MHC+CD11b+ monocytic/macrophagic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Costimulation of T-cell-mediated tumor immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Apoptosis and cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Myelodysplasia in a child with Beckwith-Wiedemann syndrome previously treated for hepatoblastoma with multi-agent chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Interleukin-2 therapy of Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Multifocal eosinophilic granuloma. Response of a patient to etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Treatment of Langerhans cell histiocytosis in children with etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

The effect of phototherapies on cutaneous lesions of histiocytosis X in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Treatment of Langerhans cell histiocytosis with alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Clinical drug resistance: the role of factors other than P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Pediatric liver transplantation. History, recent innovations, and outlook for the future

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Umbilical cord blood: a novel alternative source of hematopoietic stem cells for bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Histiocytosis X--comparison of three treatment regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Mechanisms of antigen uptake for presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Expression and functional significance of an additional ligand for CTLA-4.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

The Pathogenesis, Diagnosis, and Treatment of Histiocytosis Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Role of allogeneic bone marrow transplantation from an HLA-identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Stem cells from bone marrow, umbilical cord blood and peripheral blood for clinical application: current status and future application

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Pulmonary histiocytosis X

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Dendritic cells in immune response induction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Experimental immunotherapies for multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Resolution of cutaneous lesions of histiocytosis X by intralesional injections of interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Langerhans-cell histiocytosis-excellent response to etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Successful treatment of two children with Langerhans' cell histiocytosis with 2'-deoxycoformycin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Langerhans cell histiocytosis and hypercalcemia: clinical response to indomethacin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Liver transplantation for Langerhans' cell histiocytosis--a case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Radiation therapy for diabetes insipidus caused by Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Remission of Langerhans cell histiocytosis with thalidomide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Cyclosporine, FK506 and other drugs in organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Apoptosis: telling cells their time is up.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Fas-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

A case report and literature review of "primary" pulmonary histiocytosis X of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Molecular mechanisms of multidrug resistance in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

1 reference

7 January 2021

Apoptosis and the maintenance of homoeostasis in the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Moderate additive immunosuppressive effect of thalidomide combined with cyclosporin A in rat cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Colchicine in the treatment of pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Successful orthotopic liver transplantation in two patients with liver failure due to sclerosing cholangitis with Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Inhibition of proliferative activity of pulmonary fibroblasts by tetrandrine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Allogeneic bone marrow transplantation in a patient with chemotherapy-resistant progressive histiocytosis X.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Diabetes insipidus secondary to Langerhans' cell histiocytosis: is radiation therapy indicated?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Fas splicing variants and their effect on apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Satisfactory remission achieved by PUVA therapy in Langerhans cell hisiocytosis in an elderly patient

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Histiocytosis X: successful treatment with recombinant interferon-alpha A

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

2-Chlorodeoxyadenosine to treat refractory histiocytosis X.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Topical nitrogen mustard: An effective treatment for cutaneous Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Dendritic cells presenting tumor antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Type I interferon inhibition of superantigen stimulation: implications for treatment of superantigen-associated disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Allogeneic bone marrow transplantation for Langerhans' cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Treatment of adult Langerhans cell histiocytosis with etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Thalidomide as replacement for steroids in immunosuppression after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Serum LDH: a marker of disease activity and its response to therapy in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Human umbilical cord blood for hematopoietic progenitor cells transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Etoposide in the treatment of six children with Langerhans cell histiocytosis (histiocytosis X)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Bone marrow transplantation in children using unrelated donors at Huddinge Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Cytokine production in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Pediatric liver transplantation for Langerhans' cell histiocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970514-1

7 January 2021

10.1016/S0889-8588(05)70514-1

Identifiers

DOI

1 reference

8 October 2017

1 reference

PubMed ID

9561904